Results 71 to 80 of about 21,302 (228)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis

International Journal of Cardiology: Heart & Vasculature, 2022
Background: Various anticoagulant therapies are prescribed to patients under physicians’ discretion and recently Direct Oral Anticoagulants(DOAC) have been under trials to evaluate their safety and efficacy.
Talal Almas, Adeena Musheer, Arooba Ejaz, Fahd Niaz Shaikh, Anousheh Awais Paracha, Fizza Raza, Maryam Sarwar Khan, Fahad Masood, Faiza Siddiqui, Saamia Raza, Muhammad Fahad Wasim, Muhammad Hasnain Mankani, Kaneez Fatima, Abdul Mannan Khan Minhas   +13 more
doaj   +1 more source

[Contraindications to DOACs in atrial fibrillation].

Nederlands tijdschrift voor geneeskunde, 2020
Sometimes there is doubt as to whether or not anticoagulants should be initiated, and if so which ones, in patients with atrial fibrillation and advanced age, increased frailty, or fall risk, kidney, or liver impairment, alcohol abuse, uncontrolled hypertension, or a history of major bleeding.
Vries, T.A.C. de, Hemels, M.E.W., Pisters, R., Jansen, R., Groot, J.R. de   +4 more
openaire   +3 more sources

Effect of Medication Intake on Dental Implant‐Related Outcomes—A Scoping Review

Clinical Oral Implants Research, EarlyView.
ABSTRACT Objective The objective of this scoping review was to evaluate the effect of systemic medications on dental implant outcomes in medically compromised patients. Material and Methods Electronic and manual searches were conducted for this scoping review.
Alberto Monje, Maria Costanza Soldini, Emilio Couso‐Queiruga, Álvaro Babiano, Vivianne Chappuis   +4 more
wiley   +1 more source

Comparing the Effect of DOAC-Stop® and DOAC-Remove® on Apixaban, Rivaroxaban and Dabigatran Prior to Thrombophilia and Lupus Testing

British Journal of Biomedical Science
BackgroundDirect oral anticoagulants (DOACs) interfere with coagulation assays potentially leading to inaccurate results. This study determined the effectiveness of DOAC-stop® and DOAC-remove® in overcoming DOAC interference.
Noor-E.-Huddah Malik, Andrew Ward, Beth Erskine   +2 more
doaj   +1 more source

DOACs – advances and limitations in real world [PDF]

Thrombosis Journal, 2016
The group of new oral anticoagulants or NOACs, now termed direct oral anticoagulants or DOACs, with their favourable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy.
openaire   +2 more sources

The relationship between DOAC levels and clinical outcomes: The measures tell the tale

Journal of Thrombosis and Haemostasis, 2020
Direct oral anticoagulants (DOACs) are increasingly used for treatment and prevention of thromboembolic diseases, used in fixed dose regimens. Although their safety and efficacy profiles are considered optimal, clinical events still occur.
M. Toorop, W. Lijfering, L. Scheres
semanticscholar   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

The importance of dosing frequency on the safety of DOACs

American Heart Journal Plus: Cardiology Research and Practice, 2022
Direct oral anticoagulants (DOACs) represent a significant advance over vitamin K antagonists, such as warfarin in patients with atrial fibrillation (AF), due to their favorable risk-benefit profile, with significant reductions in stroke and serious bleeding, particularly intracranial hemorrhage.1 Although as class, DOACs tend to reduce major bleeding ...
openaire   +3 more sources

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton, A. Rapani, F. Costantinides, V. Nicolin, D. Cuhureanu, R. Di Lenarda   +5 more
wiley   +1 more source